Moleculin Extends Cash Runway to Q1 2027, Sets MIRACLE Trial Milestones
MBRX has more than doubled off its 52-week low of $0.161.
Summary
Moleculin now expects its cash position, including the recent $9.3M raise, to fund operations into Q1 2027. The company also provided specific MIRACLE trial milestones: enrollment completion in September 2026, efficacy readout by February 2027, and Part B initiation in 1H 2027. This follows the 10-Q filed yesterday that reiterated going concern doubts and Nasdaq delisting risk. The extended runway and concrete trial timeline reduce near-term financing overhang, though the company remains pre-revenue with a $4M market cap. Watch for the September enrollment milestone as the next operational checkpoint.
At the time of this announcement, MBRX was trading at $0.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1M. The 52-week trading range was $0.16 to $17.38. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.